Amneal Pharmaceuticals, Inc. AMRX Estimated Litigation Liability, Noncurrent
Estimated Litigation Liability, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s estimated litigation liability, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s estimated litigation liability, noncurrent?
- Amneal Pharmaceuticals, Inc. (AMRX) reported estimated litigation liability, noncurrent of $70.02M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s estimated litigation liability, noncurrent changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s estimated litigation liability, noncurrent decreased by 4.1% year-over-year, from $72.98M to $70.02M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s estimated litigation liability, noncurrent?
- Over 2 years (2023 to 2025), Amneal Pharmaceuticals, Inc.'s estimated litigation liability, noncurrent has grown at a 1407.6% compound annual growth rate (CAGR), from $316K to $71.82M.